Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9835
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCandido, Riccardoen
dc.contributor.authorFabris, Brunoen
dc.contributor.authorCooper, Mark Een
dc.date.accessioned2015-05-15T23:05:35Z
dc.date.available2015-05-15T23:05:35Z
dc.date.issued2002-03-01en
dc.identifier.citationIdrugs : the Investigational Drugs Journal; 5(3): 237-65en
dc.identifier.govdoc15562336en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9835en
dc.description.abstractDiabetic nephropathy is now the leading cause of end-stage renal disease in the Western world. Renal disease develops secondary to long-standing hyperglycemia and hemodynamic alterations, which activate a common pathway that ultimately leads to the renal damage. Current strategies to treat diabetic nephropathy include optimization of glycemic control and treatment of glomerular and systemic hypertension. Although these strategies can slow the progression of proteinuria and decline in renal function, diabetic nephropathy remains a huge clinical problem. It is anticipated that future treatment modalities for preventing and treating diabetic nephropathy will involve drugs that modulate common pathogenetic pathways, possibly acting to inhibit both metabolic and hemodynamically induced forms of renal injury. These include inhibitors of growth factor and cytokine release or action, and inhibitors of intracellular second messengers. Although most of these agents have only been investigated in vitro, in animal experiments, or in relatively short-term human studies, these studies suggest that therapeutic strategies which involve a multifactorial approach may be more successful in the treatment of diabetic kidney disease than drugs which influence only one pathway.en
dc.language.isoenen
dc.titleTreatment for diabetic nephropathy - a review of the recent patent literature.en
dc.typeJournal Articleen
dc.identifier.journaltitleIDrugs : the investigational drugs journalen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Waterdale Road, Heidelberg West, Victoria 3081, Australiaen
dc.description.pages237-65en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15562336en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.